PAS
OVID icon

Point72 Asia (Singapore)’s Ovid Therapeutics OVID Stock Holding History

Point72 Asia (Singapore)’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$24.9K Sell
19,173
-19,209
-50% -$16.6K ﹤0.01% 670
2025
Q2 		$12.7K Buy
+38,382
New +$11.6K ﹤0.01% 779

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Point72 Asia (Singapore)'s OVID Position: Q3 2025 in Review

Point72 Asia (Singapore) reduced its Ovid Therapeutics (OVID) stake by 50% in Q3 2025, selling an estimated $16.6K and leaving 19,173 shares worth $24.9K. The position accounts for ﹤0.01% of the portfolio, ranked #670.

Point72 Asia (Singapore) first reported a position in OVID in Q2 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

  • Point72 Asia (Singapore) held 19,173 shares of Ovid Therapeutics worth $24.9K as of Q3 2025.
  • Point72 Asia (Singapore) sold 19,209 Ovid Therapeutics shares in Q3 2025, an estimated $16.6K.
  • Ovid Therapeutics made up ﹤0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #670 holding.
  • Point72 Asia (Singapore) first reported a position in Ovid Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.